The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Inhibition of interleukin‐33 signaling attenuates the severity of experimental arthritis
Open accessAbstract
Objective: Interleukin‐33 (IL‐33; or, IL‐1F11) was recently identified as the ligand of the IL‐1 family receptor T1/ST2. The aim of this study was to examine IL‐33 production in human and mouse joints and to investigate the role of IL‐33 and T1/ST2 in experimental arthritis. Methods: IL‐33 expression was examined in human synovial tissue, rheumatoid arthritis (RA) synovial fibroblasts, and arthritic mouse joints. Mice with collagen‐induced arthritis (CIA) were treated with blocking anti‐ST2 antibody or control antibody beginning at the onset of disease. Arthritis severity was assessed by clinical and histologic scoring. Draining lymph node (LN) cell responses were examined ex vivo, and joint messenger RNA (mRNA) was used for expression profiling. Results: IL‐33 was highly expressed in human RA synovium. In cultured synovial fibroblasts, IL‐33 expression was strongly induced by IL‐1β and/or tumor necrosis factor α. Furthermore, IL‐33 mRNA was detected in the joints of mice with CIA and increased during the early phase of the disease. Administration of a blocking anti‐ST2 antibody at the onset of disease attenuated the severity of CIA and reduced joint destruction. Anti‐ST2 antibody treatment was associated with a marked decrease in interferon‐γ production as well as with a more limited reduction in IL‐17 production by ex vivo–stimulated draining LN cells. Finally, RANKL mRNA levels in the joint were reduced by anti‐ST2 treatment. Conclusion: IL‐33 is produced locally in inflamed joints, and neutralization of IL‐33 signaling has a therapeutic effect on the course of arthritis. These observations suggest that locally produced IL‐33 may contribute to the pathogenesis of joint inflammation and destruction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Acosta-Rodriguez, E. V., Napolitani, G., Lanzavecchia, A., & Sallusto, F. (2007) · Nature Immunology · doi:10.1038/ni1496 · Cited by 1,857
Th17: An Effector CD4 T Cell Lineage with Regulatory T Cell Ties
Weaver, C. T., Harrington, L. E., Mangan, P. R., Gavrieli, M., & Murphy, K. M. (2006) · Immunity · doi:10.1016/j.immuni.2006.06.002 · Cited by 1,422
Carriere, V., Roussel, L., Ortega, N., Lacorre, D.-A., Americh, L., Aguilar, L., Bouche, G., & Girard, J.-P. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606854104 · Cited by 966
Cited by
The IL-1 family: regulators of immunity
Sims, J. E., & Smith, D. E. (2010) · Nature Reviews Immunology · doi:10.1038/nri2691 · Cited by 1,418
Self-citationInterleukin-33 in health and disease
Liew, F. Y., Girard, J.-P., & Turnquist, H. R. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.95 · Cited by 1,147
Disease-associated functions of IL-33: the new kid in the IL-1 family
Liew, F. Y., Pitman, N. I., & McInnes, I. B. (2010) · Nature Reviews Immunology · doi:10.1038/nri2692 · Cited by 1,003
Interleukin‐33 (IL‐33): A nuclear cytokine from the IL‐1 family
Cayrol, C., & Girard, J. (2018) · Immunological Reviews · doi:10.1111/imr.12619 · Cited by 879
Anti-inflammatory and immune-regulatory cytokines in rheumatoid arthritis
Chen, Z., Bozec, A., Ramming, A., & Schett, G. (2019) · Nature Reviews Rheumatology · doi:10.1038/s41584-018-0109-2 · Cited by 719
Metadata
- Authors
- Palmer, G., Talabot‐Ayer, D., Lamacchia, C., Toy, D., Seemayer, C. A., Viatte, S., Finckh, A., Smith, D. E., & Gabay, C.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2009-02-26
- Volume
- 60
- Issue
- 3
- Pages
- 738-749
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2013953689
- Cited by
- 313
- References
- 3
- FWCI
- 12.22
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inhibition of interleukin‐33 signaling attenuates the severity of experimental arthritis. https://app.cochat.ai/papers/10.1002/art.24305
- The paper
- Palmer, G., Talabot‐Ayer, D., Lamacchia, C., Toy, D., Seemayer, C. A., Viatte, S., Finckh, A., Smith, D. E., & Gabay, C. (2009). Inhibition of interleukin‐33 signaling attenuates the severity of experimental arthritis. Arthritis & Rheumatism. https://doi.org/10.1002/art.24305
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.